BARD1 COLLABORATOR UNIVERSITY OF QUEENSLAND ANNOUNCES PROMISING OVARIAN CANCER DATA

- **University of Queensland researchers have unveiled promising results for a potential exosome-based blood test for ovarian cancer**
- **BARD1's RUO EXO-NET® product has been used by the researchers to isolate exosomes within 15 minutes, with high purity and yield**
- **EXO-NET could facilitate the development of commercial exosome-based tests for cancer**

Melbourne, Australia, 28 July 2021: BARD1 Life Sciences Limited (ASX:BD1) (**BARD1** or the **Company**) is pleased to collaborate with researchers at the University of Queensland (UQ) who are using the EXO-NET® product to develop a novel test for ovarian cancer based on exosomes isolated from the blood of cancer patients.

UQ researchers told Brisbane's The Courier-Mail on 26th July 2021 that: "We've had extremely encouraging results so far in tests validated in 500 women. The accuracy of our technology to identify positive cases was greater than 90 per cent, suggesting it could be an ideal first-line test for population screening."

Exosomes are a specific type of extracellular vesicle, which are tiny particles that are released by most cells, including cancer cells, into body fluids including the bloodstream, urine, cerebrospinal fluid and saliva. Exosomes provide valuable clues to a person's health as they contain molecules from the host cells that can be used for diagnosis and treatment of disease, including cancer.

Associate Professor Carlos Salomon, the lead researcher of UQ's ovarian cancer project, has used BARD1's next-generation pan-exosome isolation and purification tool, EXO-NET, with very positive results. "EXO-NET provides a simple and rapid exosome capture technology, which has been used with our ovarian cancer test developed at UQ and has great potential for clinical applications," said Dr Salomon on BARD1's recent EXO-NET video.

BARD1 has already been working with UQ's commercialisation company UniQuest, who negotiated the agreement, which provides BARD1 with an exclusive option to licence the technology developed at UQ. BARD1's Chief Scientific Officer, Dr Peter French, said, "We are very excited to be working with Dr Salomon's research team at UQ on the development of a potential exosome-based commercial test for ovarian cancer. EXO-NET uniquely solves the sample preparation problems encountered using traditional exosome capture methods by providing fast, accurate and scalable capture of exosomes."

BARD1's CEO, Dr Leearne Hinch said, "The University of Queensland's exosome-based ovarian cancer test showcases the advantages of EXO-NET and its potential to assist the translation of research discoveries into commercial diagnostic tests. We look forward to continuing to work with Associate Professor Salomon and the University of Queensland to bring this, and potentially other exosome-based cancer tests to the market."

Earlier research contributing to this diagnostic test was supported by a grant from the Ovarian Cancer Research Foundation.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
CEO
E leearne@bard1.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@bard1.com
M +61 417 203 021

ABOUT BARD1 LIFE SCIENCES LTD

BARD1 Life Sciences Ltd (ASX:BD1) (**BARD1** or the **Company**) is a leading Australian diagnostics company with an innovative portfolio of diagnostic technologies and products. The Company is focused on developing and commercialising diagnostic solutions for healthcare professionals and patients. BARD1 has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes tests in development for ovarian and breast cancers, and research-stage projects for prostate and pancreatic cancers. For more information on BARD1, see www.bard1.com and www.exo-net.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.